Apnimed (APMD) began trading on the Nasdaq on Fri 31 Jul 26

Sector: Pharmaceutical industry
Employees 65

Founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 

Headquartered in Cambridge, MA
Website apnimed.com
Apnimed opened at $22 after pricing IPO at $16/share 

 

• Apnimed (APMD) is off to a successful public-market debut, with its upsized 12.0 mln share IPO pricing at $16 -- the top of its $14--$16 range -- before opening at $22 for a 38% gain, signaling strong investor demand for the late-stage sleep-medicine developer.
• The biopharmaceutical company is developing oral therapies for sleep-related breathing disorders, led by Oxnimbi, also known as AD109, a once-nightly combination drug designed to improve upper-airway muscle activity and prevent airway collapse in patients with obstructive sleep apnea.
• APMD's primary end market is the large OSA population, where current treatment is dominated by devices such as CPAP, giving a convenient oral therapy the potential to expand diagnosis, treatment adoption, and patient compliance if approved.
• The company submitted an NDA for Oxnimbi in April 2026 following positive Phase 3 trials, and the FDA accepted the application for review in July, making regulatory approval and commercialization the central near-term catalysts for the story.
• For the three months ended March 31, 2026, APMD reported $84.8 mln of related-party revenue, up sharply from $3.1 mln a year earlier, while income from operations swung to $68.0 mln from a $27.1 mln loss.
• That financial improvement should be viewed cautiously, however, because the revenue was tied primarily to licensing, know-how, and research-service arrangements with its SASS joint venture rather than recurring commercial product sales, meaning the IPO's longer-term success will ultimately depend on Oxnimbi's approval, launch execution, reimbursement, and physician and patient adoption.